Literature DB >> 30390763

Risk Factors for Ovarian Carcinoma.

Adrianne R Mallen1, Mary K Townsend2, Shelley S Tworoger3.   

Abstract

Ovarian cancer is the leading gynecologic killer of women in the United States. At diagnosis, most women present with advanced-stage disease. There are currently no effective screening strategies for average-risk women, thus understanding disease development and progression is important for developing risk-reduction strategies and identifying high-risk populations who can benefit from preventive surgery. Cancer epidemiology has greatly contributed to the understanding of this complex, heterogeneous disease by identifying various factors that may modify disease development. This article comprehensively reviews the current evidence regarding risk factors using the newest epidemiologic research for further insight into this lethal disease.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Descriptive epidemiology; Ovarian cancer; Risk factors; Risk reduction; Tumor heterogeneity

Mesh:

Year:  2018        PMID: 30390763     DOI: 10.1016/j.hoc.2018.07.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  6 in total

1.  The roles of HOXB8 through activating Wnt/β-catenin and STAT3 signaling pathways in the growth, migration and invasion of ovarian cancer cells.

Authors:  Lidan Liu; Lifei Wang; Xiujuan Li
Journal:  Cytotechnology       Date:  2022-01-03       Impact factor: 2.058

2.  Surgery in platinum-resistant recurrent epithelial ovarian carcinoma.

Authors:  Ling-Qin Zhao; Wen Gao; Ping Zhang; Ying-Li Zhang; Chen-Yan Fang; Hua-Feng Shou
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

3.  Impact of Rurality on Stage IV Ovarian Cancer at Diagnosis: A Midwest Cancer Registry Cohort Study.

Authors:  Kristin S Weeks; Charles F Lynch; Michele West; Megan McDonald; Ryan Carnahan; Sherri L Stewart; Mary Charlton
Journal:  J Rural Health       Date:  2020-02-20       Impact factor: 5.667

4.  Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib.

Authors:  Romane Florent; Louis-Bastien Weiswald; Bernard Lambert; Emilie Brotin; Edwige Abeilard; Marie-Hélène Louis; Guillaume Babin; Laurent Poulain; Monique N'Diaye
Journal:  Cell Death Dis       Date:  2020-05-18       Impact factor: 8.469

5.  Bi-directional Mendelian randomization of epithelial ovarian cancer and schizophrenia and uni-directional Mendelian randomization of schizophrenia on circulating 1- or 2-glycerophosphocholine metabolites.

Authors:  Charleen D Adams; Susan L Neuhausen
Journal:  Mol Genet Metab Rep       Date:  2019-11-06

Review 6.  Reactive Oxygen Species Bridge the Gap between Chronic Inflammation and Tumor Development.

Authors:  Weihua Yu; Yongmei Tu; Zi Long; Jiangzheng Liu; Deqin Kong; Jie Peng; Hao Wu; Gang Zheng; Jiuzhou Zhao; Yuhao Chen; Rui Liu; Wenli Li; Chunxu Hai
Journal:  Oxid Med Cell Longev       Date:  2022-06-28       Impact factor: 7.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.